For the first time, CAR-T anticancer drugs at the million-yuan level have been included in China's basic medical insurance, and patients' out-of-pocket costs have been reduced to within 100,000 yuan.
The million-level CAR-T cancer therapy,药明巨诺瑞基奥仑赛注射液 (商品名: 倍诺达®), has been included in China's basic medical insurance catalog for the first time, reducing patient out-of-pocket costs to within 100,000 RMB after reimbursement. The price reduction is attributed to the domestic production of key raw materials, which has significantly lowered manufacturing costs.
Why it matters. Patients receiving this high-cost cancer treatment will face substantially lower financial burden, marking a significant shift in affordability for a previously 'tiered' (million-yuan) therapy within the national health system.